~5 spots leftby Aug 2025

Psilocybin for Trauma

(NWTTPS Trial)

Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: NWTraumatherapies
No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests the use of psilocybin microdosing to help patients with chronic illnesses like PTSD and depression. Psilocybin, found in certain mushrooms, helps the brain form new pathways, reducing negative thoughts. This approach targets patients who don't respond well to traditional treatments. Psilocybin has shown promise as a treatment for major depressive disorder and was designated as breakthrough therapy by the FDA.

Research Team

RM

Ross M Allison, Provider

Principal Investigator

NW Therapies Trauma Unit

Eligibility Criteria

This trial is for individuals with traumatic brain injury or wounds who have chronic conditions like PTSD, depression, MS, HIV, and Long Haulers Syndrome. Participants must consent to the study and be evaluated by a psychiatrist or therapist. Those with cardiovascular complications cannot join.

Inclusion Criteria

Administrator
On Boarding Plant Medicine Specialist
Psychiatrist
See 2 more

Exclusion Criteria

I have a heart condition.

Treatment Details

Interventions

  • Trauma (Psychedelic)
Trial OverviewThe study tests enhanced micro-dosing of psilocybin (a compound similar to serotonin) for trauma patients. Doses range from 0.15g to 0.33g every other day and up to 1.5 grams monthly for maintenance, aiming to create new neural pathways and alleviate symptoms.
Participant Groups
4Treatment groups
Experimental Treatment
Group I: PsychiatristExperimental Treatment1 Intervention
Psychiatrist QC scaling back SSRI's replacing with psilocybin.
Group II: Plant Medicine On BoardingExperimental Treatment1 Intervention
The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every M/W/F with a tailored dose of plant medicine psilocybin in the enhanced micro dose levels or 0.15g. to 0.33g with a monthly dose of 1 gram to 1.5 grams. Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
Group III: ParticipantExperimental Treatment1 Intervention
0.15g. thru 0.33g. tailored to participant, then Monthly a 1 time dose of 1gram to 1.5 grams dose of non-synthesized plant medicine psilocybin.
Group IV: On-Boarding Plant Medicine SpecialistExperimental Treatment1 Intervention
The On-Boarding Provider will control dosage of the plant medicine via Telehealth.

Find a Clinic Near You

Who Is Running the Clinical Trial?

NWTraumatherapies

Lead Sponsor

Trials
1
Recruited
30+

World Health Organization

Collaborator

Trials
236
Recruited
1,620,000+